Understanding Human Metapneumovirus (HMPV)

 

Table of Content:

• Introduction
• Virology and Classification
• Epidemiology
• Transmission and Pathogenesis
• Clinical Manifestations
• Diagnosis
• Treatment and Management
• Vaccines and Research
• Public Health Impact
• Key Outbreaks
• Future Perspectives
• Conclusion
• References

Disclaimer: The content provided on this website is intended solely for academic, educational, and general informational purposes. It is not meant to be used as medical advice, diagnosis, or treatment. If you are feeling unwell, please seek guidance from a physician, doctor, or qualified healthcare professional.

Introduction

Human metapneumovirus (HMPV) is an important respiratory virus that affects individuals of all ages, particularly young children and the elderly. It can lead to illnesses ranging from mild cold-like symptoms to severe respiratory infections.

What is Human Metapneumovirus?

HMPV is a member of the Pneumoviridae family and is characterized by its single-stranded RNA genome. It causes respiratory infections similar to those caused by other viruses, such as respiratory syncytial virus (RSV). Symptoms include cough, fever, and wheezing, with severe cases potentially leading to pneumonia.

Discovery and Historical Background

HMPV was first identified in 2001 by researchers in the Netherlands. However, serological evidence suggests it may have been present in human populations since the 1950s. Initially classified within the Paramyxoviridae family, it was reclassified into the Pneumoviridae family in 2016. The virus has two main genetic lineages, A and B, which exhibit variations that can influence its epidemiology and clinical impact.

Virology and Classification

Family and Genus

Human metapneumovirus (HMPV) belongs to the family Pneumoviridae and the genus Metapneumovirus. This classification places HMPV among other respiratory viruses, highlighting its relevance in public health due to its role in respiratory infections, particularly in vulnerable populations such as infants and the elderly.

Genetic Structure

HMPV has a non-segmented, negative-sense single-stranded RNA genome approximately 13.3 kilobases in length. Its genome consists of eight genes organized in the order: N-P-M-F-M2-SH-G-L. Notably, HMPV lacks the non-structural genes NS1 and NS2 found in related viruses like respiratory syncytial virus (RSV). This genetic structure contributes to its classification and evolutionary relationships with other viruses.

Types and Strains

HMPV is categorized into two main subgroups: A and B, each containing distinct genetic variants. Subgroup A includes subtypes A1 and A2, while subgroup B includes subtypes B1 and B2. These subgroups exhibit genetic diversity that can influence the severity of infections and the virus's epidemiology. The G attachment protein shows significant variability, which may affect how the virus interacts with host cells.

Epidemiology

Data source from: https://worldhealthorg.shinyapps.io/flunetchart/

Geographic Distribution

Human metapneumovirus (HMPV) is found worldwide, with studies indicating its presence in various regions, including North America, Europe, and Asia. The prevalence of HMPV infections can vary by geographic location and season. For instance, a study in Córdoba, Argentina, reported a prevalence of 20.3% among hospitalized patients with acute respiratory infections, highlighting its widespread occurrence in different populations.

Seasonality

HMPV exhibits clear seasonal patterns, with peaks typically occurring during late winter and spring. Research shows that over half of HMPV infections occur in spring (March to May), with the highest detection rates often observed in April. This seasonal distribution is consistent across various studies, indicating that HMPV tends to circulate more actively during specific months of the year.

Populations at Risk

Certain populations are at higher risk for severe HMPV infections. These include:

Infants and Young Children: The highest prevalence is observed in children under 5 years of age, particularly those under 1 year old. Studies show that infants represent a significant portion of HMPV cases.

• Elderly Individuals: Older adults, especially those over 60 years old, are also at increased risk for severe respiratory illness due to HMPV.
• Immunocompromised Patients: Individuals with weakened immune systems are more susceptible to severe outcomes from HMPV infections.

Overall, understanding the epidemiology of HMPV is crucial for public health strategies aimed at preventing and managing respiratory infections in vulnerable populations.

Transmission and Pathogenesis

Modes of Transmission

Human metapneumovirus (HMPV) spreads primarily through several key modes:

• Respiratory Droplets: The most common mode of transmission occurs when an infected person coughs or sneezes, releasing droplets containing the virus into the air. These droplets can be inhaled by individuals nearby, leading to infection.
• Direct Contact: HMPV can also spread through direct contact with an infected individual. This includes actions such as touching, kissing, or shaking hands with someone who has the virus. If respiratory secretions are present on a person's hands and they touch another person, transmission can occur.
• Contaminated Surfaces: The virus can survive on surfaces for several hours. If a person touches a contaminated surface and then touches their face (mouth, nose, or eyes), they may become infected.

Replication Cycle

The replication cycle of HMPV involves several steps:

• Attachment: HMPV attaches to host cells through its surface glycoproteins (G and F proteins), which interact with receptors on the host cell membrane.
• Entry: Once attached, the virus enters the host cell via endocytosis, where it is engulfed by the cell membrane.
• Release of Viral RNA: Inside the cell, the viral envelope fuses with the endosomal membrane, releasing the viral RNA into the cytoplasm.
• Replication and Transcription: The viral RNA is then replicated and transcribed into messenger RNA (mRNA) using the host's cellular machinery.
• Assembly: Newly synthesized viral proteins and RNA genomes are assembled into new virions within the host cell.
• Budding: The new virions bud off from the host cell membrane, acquiring their envelope in the process, and are released to infect other cells.

Mechanisms of Disease

HMPV primarily causes respiratory illness through several mechanisms:

• Infection of Respiratory Epithelial Cells: The virus targets epithelial cells in the respiratory tract, leading to cell damage and inflammation. This can result in symptoms such as cough, wheezing, and difficulty breathing.
• Immune Response: The body’s immune response to HMPV infection can contribute to disease severity. Inflammatory cytokines are released in response to viral infection, which can lead to further respiratory distress and complications like bronchiolitis or pneumonia.
• Reinfections: Individuals can be reinfected with HMPV due to the presence of different viral genotypes and insufficient immunity from previous infections. This highlights the virus's ability to evade immune responses over time.

Understanding these aspects of transmission and pathogenesis is crucial for developing effective prevention strategies and treatments for HMPV infections.

Pathogenesis

Respiratory Tract Infection

HMPV primarily targets the respiratory tract, leading to infections, inflammation, and damage to the airway epithelium.

Host Immune Response

• HMPV disrupts the host's innate immune system through specific mechanisms.
• The virus interferes with pattern recognition receptors (PRRs) like toll-like receptors (TLRs), retinoic acid-inducible gene-like receptors (RLRs), and other signaling molecules to evade immune responses.
• HMPV infections may trigger a delayed and minimal immune response, impairing cytotoxic T-lymphocyte activity and hindering effective virus clearance during primary infection.
• The virus inhibits dendritic cell activity, reducing the activation of antigen-specific T cells, which compromises virus clearance and increases the likelihood of reinfection.
• HMPV limits the proliferation of antigen-specific CD4+ T cells, impairing long-term immunity.
• HMPV infection induces TLR-dependent signaling while simultaneously inhibiting the production of type I and type III interferons, essential for antiviral defense.

Image source: Gálvez, N. M. S., Andrade, C. A., Pacheco, G. A., Soto, J. A., Stranger, V., Rivera, T., Vásquez, A. E., & Kalergis, A. M. (2021). Host Components That Modulate the Disease Caused by hMPV. Viruses, 13(3), 519. https://doi.org/10.3390/v13030519

Mucin 19 and Mucus Production

• Mucus production is a hallmark of HMPV infection, though its role in pathogenesis and immune response remains unclear.
• Mucin 19, a key component of mucus, is predominantly expressed in the respiratory tract during HMPV infection.
• Mucin 19 contributes to immune activation and plays a role in HMPV-induced pathogenesis.

Inflammation

• HMPV infection triggers the release of chemokines and cytokines, resulting in immune cell infiltration and inflammation.
• Studies in BALB/c mice and cotton rats show that HMPV induces pulmonary inflammatory changes, increasing levels of interleukins (IL-2, IL-4, IL-8), interferons (IFN-α), macrophage inflammatory protein 1α, and monocyte chemotactic proteins in the lungs and bronchoalveolar lavage fluid.
• These changes cause perivascular and peribronchiolar infiltration, exacerbating inflammation.

Tissue Damage

The virus's cytopathic effects damage the respiratory epithelium, resulting in intra-alveolar foamy macrophages, haemosiderin-laden macrophages, smudge cells, alveolar damage, and hyaline membrane formation.

Recovery

• In most cases, the immune system eventually controls and clears the infection.
• However, in individuals with underlying risk factors, the infection may be more severe, leading to a prolonged recovery period.

Image source: Panda, S., Mohakud, N. K., Pena, L., & Kumar, S. (2014). Human metapneumovirus: review of an important respiratory pathogen. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 25, 45–52. https://doi.org/10.1016/j.ijid.2014.03.1394

Clinical Manifestations

Symptoms in Children

In children, particularly those under the age of 5, human metapneumovirus (HMPV) often presents with mild respiratory symptoms that can escalate in severity. Common symptoms include:

• Cough
• Runny nose or nasal congestion
• Fever
• Sore throat
• Wheezing

Most cases are mild and resolve within a week, but about 5% to 16% of children may develop more severe complications such as bronchiolitis or pneumonia. Infants under one year old are particularly vulnerable and may experience difficulty feeding due to respiratory distress. HMPV is responsible for approximately 10% to 12% of respiratory illnesses in children, making it a significant cause of hospitalization during peak seasons.

Symptoms in Adults

In adults, HMPV can also lead to mild upper respiratory symptoms similar to those seen in children. Common symptoms include:

• Cough
• Fever
• Nasal congestion
• Sore throat

However, adults with pre-existing health conditions or weakened immune systems may experience more severe manifestations, including:

• Wheezing
• Shortness of breath
• Asthma exacerbations
• Pneumonia

Older adults and those over 65 years of age are at a higher risk for severe illness and complications from HMPV infections.

Severe and Complicated Cases

Severe cases of HMPV can lead to significant respiratory complications, particularly in high-risk populations such as infants, the elderly, and immunocompromised individuals. Complications may include:

• Bronchiolitis: This condition is most common in young children and can be life-threatening in rare cases.
• Pneumonia: HMPV can lead to viral pneumonia, which may require hospitalization for supportive care.
• Acute asthma exacerbations: Patients with asthma may experience worsening symptoms during an HMPV infection.

In severe instances, medical intervention may be necessary to monitor and manage respiratory distress and other complications. It is crucial for individuals experiencing worsening symptoms—such as difficulty breathing or persistent high fever—to seek medical attention promptly.

Diagnosis

Laboratory Methods

The diagnosis of human metapneumovirus (HMPV) typically involves a combination of clinical evaluation and laboratory testing. The primary laboratory methods used for detecting HMPV include:

• Reverse Transcription Polymerase Chain Reaction (RT-PCR): This is the most widely used method for HMPV detection. RT-PCR detects viral RNA in respiratory samples, providing a reliable and sensitive means of diagnosis. Variants of this method include multiplex RT-PCR, which allows for the simultaneous detection of multiple respiratory viruses in a single test.
• Enzyme-Linked Immunosorbent Assay (ELISA): This test identifies antibodies or viral antigens in the patient’s sample. It can confirm the presence of HMPV by detecting specific proteins associated with the virus.
• Nucleic Acid Amplification Tests (NAAT): These tests are sensitive and can detect the viral genome, making them effective for diagnosing HMPV infections.
• Immunofluorescence Assays: These tests help detect viral antigens in respiratory specimens, providing another method for confirming HMPV infection.
• Viral Culture: Although less common now due to the rise of molecular methods, viral culture can still be utilized to isolate HMPV from respiratory samples. However, it is time-consuming and less sensitive compared to PCR-based methods.

Imaging and Differential Diagnosis

In cases where severe respiratory symptoms are present, imaging studies such as chest X-rays may be conducted to assess lung involvement and rule out other conditions like pneumonia or bronchitis.

Differential Diagnosis: When diagnosing HMPV, it is essential to differentiate it from other respiratory viruses that cause similar symptoms, including:

• Respiratory syncytial virus (RSV)
• Influenza viruses
• Parainfluenza viruses
• Rhinoviruses
• Adenoviruses

A thorough clinical history and laboratory testing help ensure accurate diagnosis and appropriate management.

Treatment and Management

Supportive Care

The primary approach to managing human metapneumovirus (HMPV) infections is supportive care, particularly since there is no specific antiviral treatment available. Supportive care includes:

• Symptom Management: Over-the-counter medications such as acetaminophen or ibuprofen can help reduce fever and alleviate pain. Decongestants may also be used to relieve nasal congestion.
• Hydration: Ensuring adequate fluid intake is crucial. For patients who are unable to maintain oral hydration, intravenous (IV) fluids may be necessary.
• Respiratory Support: In cases of severe respiratory distress, supplemental oxygen may be required. This could include high-flow nasal cannula or mechanical ventilation for patients experiencing acute respiratory failure, especially those with pre-existing respiratory or cardiac conditions.
• Corticosteroids: In some instances, oral corticosteroids like prednisone may be prescribed to reduce inflammation in the airways, particularly for patients with wheezing or asthma exacerbations.

Antiviral Therapies (if applicable)

Currently, there are no specific antiviral medications approved for HMPV. However, some studies have investigated the use of ribavirin, an antiviral drug traditionally used for treating respiratory syncytial virus (RSV). Ribavirin has shown potential in vitro activity against HMPV and may be considered in certain cases, particularly for:

• Immunocompromised Patients: Some clinical experiences suggest that ribavirin combined with intravenous immunoglobulin (IVIG) may benefit severely ill immunocompromised patients. However, this treatment is not widely established and requires further research.
• Administration Considerations: Ribavirin can have teratogenic effects and must be administered with caution, especially in pregnant healthcare providers. It is typically given via aerosolized delivery or orally in clinical settings.

Preventive Measures

Preventing HMPV infections involves general measures aimed at reducing the transmission of respiratory viruses:

• Hand Hygiene: Regular handwashing with soap and water or using hand sanitizer can help prevent the spread of the virus.
• Respiratory Hygiene: Covering coughs and sneezes with a tissue or elbow and wearing masks in crowded places can minimize droplet transmission.
• Avoiding Close Contact: Keeping distance from individuals exhibiting cold-like symptoms can help reduce the risk of infection.
• Droplet Precautions: In healthcare settings, patients diagnosed with HMPV should be placed on droplet precautions to limit the spread of the virus.

While vaccines for HMPV are currently under research, none are available for public use at this time.

Vaccines and Research

Current Developments

As of January 2025, human metapneumovirus (HMPV) remains without a vaccine, despite being discovered over 20 years ago. Recent reports highlight a surge in HMPV cases in China, raising concerns about its impact on public health. Researchers are actively exploring vaccine options, particularly in light of the recent development of a vaccine for respiratory syncytial virus (RSV), which shares similarities with HMPV. There is ongoing research aimed at creating a combined vaccine that could protect against both RSV and HMPV, leveraging the advancements made in RSV vaccine development.

Challenges in Vaccine Development

The development of a vaccine for HMPV faces several challenges:

• Lack of Urgency: Although HMPV is a common respiratory virus, it typically causes mild illness in most populations. This has resulted in less urgency for vaccine development compared to other respiratory viruses that pose greater pandemic threats, such as SARS-CoV-2.
• Immunological Complexity: HMPV has shown variability with different strains and genotypes, complicating the development of a universal vaccine. The virus mutates over time, which can hinder the effectiveness of a vaccine designed to target specific strains.
• Funding and Resources: Research funding for HMPV has historically been limited compared to more prominent viral threats. This lack of investment can slow progress in both understanding the virus and developing effective vaccines.
• Existing Immunity: Many individuals have some pre-existing immunity to HMPV due to prior infections throughout their lives, which can complicate vaccine efficacy studies.

Despite these challenges, researchers continue to investigate potential vaccine candidates and strategies to enhance immune responses against HMPV.

Public Health Impact

Burden on Healthcare Systems

Human metapneumovirus (HMPV) places a notable burden on healthcare systems, particularly during its peak seasons in late winter and early spring. While HMPV does not reach the same level of global impact as influenza or COVID-19, it is responsible for a significant number of respiratory infections. In hospitalized children, HMPV accounts for approximately 5% to 7% of acute respiratory infections (ARIs). The recent increase in HMPV cases reported in northern China indicates a potential strain on healthcare resources, with hospitals experiencing heightened demand for respiratory care.

Mortality and Morbidity Rates

The morbidity associated with HMPV is particularly concerning among vulnerable populations, including infants, the elderly, and individuals with compromised immune systems. While most infections result in mild symptoms that resolve within a week or two, severe cases can lead to complications such as bronchiolitis and pneumonia. In children under one year old, the risk of developing lower respiratory tract infections is notably higher, with studies indicating that 5% to 16% of infected children may require hospitalization due to severe illness.

Mortality rates related to HMPV are generally low; however, they can increase significantly in high-risk groups. For instance, frail older adults with underlying health conditions may experience severe outcomes, including hospitalization and intensive care unit admissions. Research has shown that HMPV infections can necessitate ICU care at rates comparable to those seen with influenza.

Key Outbreaks

Notable Cases Worldwide

Recent outbreaks of human metapneumovirus (HMPV) have garnered attention, particularly in China, where health officials reported a significant rise in cases during the winter months. As of early January 2025, data from the Chinese CDC indicated an increase in HMPV infections alongside other respiratory viruses, such as influenza and respiratory syncytial virus (RSV). The surge in cases aligns with typical seasonal patterns for respiratory viruses, which tend to peak during colder months when people are more likely to gather indoors.

In India, the first confirmed cases of HMPV were reported in early January 2025, with seven individuals testing positive across various cities, including Nagpur and Bengaluru. Health officials reassured the public that there was no cause for alarm, emphasizing that HMPV is known to cause upper and lower respiratory diseases across all age groups.

Lessons Learned

The recent outbreaks highlight several important lessons:

• Public Awareness: Increased public awareness about HMPV is essential. Many individuals may be unfamiliar with the virus, leading to confusion and concern during outbreaks. Clear communication from health authorities can help mitigate panic and promote understanding of the virus's typical behavior.
• Surveillance Systems: Effective surveillance systems are crucial for monitoring respiratory viruses. The establishment of robust monitoring protocols can facilitate early detection of outbreaks and help healthcare systems prepare accordingly.
• Seasonal Preparedness: Understanding the seasonal nature of respiratory viruses like HMPV allows for better preparedness in healthcare settings. Anticipating increases in respiratory infections during winter months can help allocate resources and implement preventive measures.
• Collaboration and Data Sharing: Global collaboration among health organizations, such as the World Health Organization (WHO), and national health agencies is vital for sharing data on viral trends and outbreaks. This collaboration can inform public health responses and improve overall management of respiratory infections.

Future Perspectives

Advances in Diagnostic Tools

Recent advancements in diagnostic tools for human metapneumovirus (HMPV) have significantly improved the ability to detect and manage infections. Rapid molecular diagnostics, such as RT-PCR and multiplex PCR assays, allow for the simultaneous detection of HMPV alongside other respiratory viruses, enhancing diagnostic accuracy and speed. These tools are particularly valuable in clinical settings where timely diagnosis can influence treatment decisions and patient outcomes. Additionally, the development of point-of-care testing devices is underway, which could facilitate quicker diagnosis in outpatient settings and reduce the burden on healthcare facilities.

Research Trends

Current research trends focus on several key areas related to HMPV:

• Vaccine Development: There is a growing interest in developing vaccines targeting HMPV, especially in light of recent outbreaks. Investigational bivalent vaccines that aim to protect against both HMPV and respiratory syncytial virus (RSV) are currently in clinical trials, highlighting a promising direction for future prevention strategies.
• Understanding Pathogenesis: Ongoing studies aim to better understand the mechanisms of disease caused by HMPV, including how it interacts with the immune system. This knowledge could lead to more effective therapeutic interventions.
• Epidemiological Studies: Researchers are conducting epidemiological studies to track the prevalence and genetic diversity of HMPV strains globally. This information is crucial for understanding how the virus spreads and evolves over time.
• Public Health Preparedness: In response to recent surges in HMPV cases, public health authorities are enhancing surveillance systems to monitor respiratory infections more effectively. This includes implementing new monitoring protocols for pneumonia of unknown origin, which can help identify emerging threats early.

The combination of advanced diagnostics and ongoing research efforts will be essential in managing HMPV infections and mitigating their impact on public health.

Conclusion

Summary of Key Points

Human metapneumovirus (HMPV) is a common respiratory virus identified in 2001, responsible for a range of respiratory illnesses, particularly in children, the elderly, and immunocompromised individuals. Key points include:

• Epidemiology: HMPV is prevalent worldwide and typically peaks during late winter and early spring. It can cause both upper and lower respiratory tract infections, with symptoms resembling those of the common cold, such as cough, fever, and nasal congestion.
• Clinical Manifestations: While most infections are mild and resolve within a week, severe cases can lead to bronchiolitis and pneumonia, necessitating hospitalization in vulnerable populations.
• Diagnosis and Treatment: Diagnosis primarily relies on molecular testing methods like RT-PCR. Currently, there is no specific antiviral treatment for HMPV; management focuses on supportive care.
• Public Health Impact: HMPV poses a significant burden on healthcare systems, especially during peak seasons. Although mortality rates are generally low, severe illness can occur in high-risk groups.

Importance of Continued Surveillance

Given the recent surge in HMPV cases in regions like China and India, continued surveillance is crucial. Monitoring trends in HMPV infections can help public health officials implement timely interventions and allocate resources effectively. Enhanced surveillance systems will also facilitate early detection of outbreaks and improve understanding of the virus's epidemiology.

As research progresses toward developing vaccines and better diagnostic tools, ongoing vigilance will be essential to mitigate the impact of HMPV on public health. By fostering awareness and preparedness, healthcare systems can better respond to future challenges posed by this virus.

Reference

• https://www.gavi.org/vaccineswork/everything-you-need-know-about-human-metapneumovirus-hmpv
• Costa-Filho, R. C., Saddy, F., Costa, J. L. F., Tavares, L. R., & Castro Faria Neto, H. C. (2025). The Silent Threat of Human Metapneumovirus: Clinical Challenges and Diagnostic Insights from a Severe Pneumonia Case. Microorganisms, 13(1), 73.
• https://doi.org/10.3390/microorganisms13010073
• https://www.scientificamerican.com/article/what-is-human-metapneumovirus-and-why-are-cases-rising-in-china/
• https://www.unmc.edu/healthsecurity/transmission/2025/01/07/indias-first-human-metapneumovirus-hmpv-cases-confirmed-but-officials-say-no-reason-to-worry/
• World Health Organization (7 January 2025). Disease Outbreak News; Trends of acute respiratory infection, including human metapneumovirus, in the Northern Hemisphere. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON550 
• https://worldhealthorg.shinyapps.io/flunetchart/
• https://www.bbc.com/news/articles/c23vjg7v7k0o
• https://edition.cnn.com/2025/01/07/health/human-metapneumovirus-hmpv-cases-china-us/index.html
• The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain
• Piñana, Maria et al. Journal of Infection, Volume 87, Issue 2, 103 - 110
• Walsh EE, Peterson DR, Falsey AR. Human Metapneumovirus Infections in Adults: Another Piece of the Puzzle. Arch Intern Med. 2008;168(22):2489–2496. doi:10.1001/archinte.168.22.2489
• https://www.lung.org/lung-health-diseases/lung-disease-lookup/human-metapneumovirus-hmpv/learn-about-human-metapneumovirus-hmpv
• https://www.apollohospitals.com/health-library/human-metapneumovirus-hmpv/
• https://www.ecdc.europa.eu/en/news-events/increase-respiratory-infections-china
• van den Hoogen, B. G., Osterhaus, D. M., & Fouchier, R. A. (2004). Clinical impact and diagnosis of human metapneumovirus infection. The Pediatric infectious disease journal, 23(1 Suppl), S25–S32. https://doi.org/10.1097/01.inf.0000108190.09824.e8
• https://www.ndtv.com/world-news/hmpv-over-20-years-after-discovery-no-vaccine-yet-for-human-metapneumovirus-7389658
• https://www.sciencemediacentre.org/expert-comments-about-hmpv-human-metapneumovirus-following-media-reports-about-cases-in-china/
• Uddin S, Thomas M. Human Metapneumovirus. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560910/
• Shahda, S., Carlos, W. G., Kiel, P. J., Khan, B. A., & Hage, C. A. (2011). The human metapneumovirus: a case series and review of the literature. Transplant infectious disease : an official journal of the Transplantation Society, 13(3), 324–328. https://doi.org/10.1111/j.1399-3062.2010.00575.x
• Jeong, S., Park, M. J., Song, W., & Kim, H. S. (2020). Advances in laboratory assays for detecting human metapneumovirus. Annals of translational medicine, 8(9), 608. https://doi.org/10.21037/atm.2019.12.42
• Pabbaraju, K., Wong, S., McMillan, T., Lee, B. E., & Fox, J. D. (2007). Diagnosis and epidemiological studies of human metapneumovirus using real-time PCR. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 40(3), 186–192. https://doi.org/10.1016/j.jcv.2007.08.004
• https://www.cdc.gov/human-metapneumovirus/about/index.html
• Rodriguez, P. E., Frutos, M. C., Adamo, M. P., Cuffini, C., Cámara, J. A., Paglini, M. G., Moreno, L., & Cámara, A. (2020). Human Metapneumovirus: Epidemiology and genotype diversity in children and adult patients with respiratory infection in Córdoba, Argentina. PloS one, 15(12), e0244093. https://doi.org/10.1371/journal.pone.0244093
• Human Metapneumovirus: Epidemiology and genotype diversity in children and adult patients with respiratory infection in Córdoba, Argentina
• Rodriguez PE, Frutos MC, Adamo MP, Cuffini C, Cámara JA, et al. (2020) Human Metapneumovirus: Epidemiology and genotype diversity in children and adult patients with respiratory infection in Córdoba, Argentina. PLOS ONE 15(12): e0244093. https://doi.org/10.1371/journal.pone.0244093
• Epidemiology, genetic characteristics, and association with meteorological factors of human metapneumovirus infection in children in southern China: A 10-year retrospective study
• Ye, Hengming et al. International Journal of Infectious Diseases, Volume 137, 40 - 47
• Yong Kwan Lim, Oh Joo Kweon, Hye Ryoun Kim, Tae-Hyoung Kim, Mi-Kyung Lee, Clinical Features, Epidemiology, and Climatic Impact of Genotype-specific Human Metapneumovirus Infections: Long-term Surveillance of Hospitalized Patients in South Korea, Clinical Infectious Diseases, Volume 70, Issue 12, 15 June 2020, Pages 2683–2694, https://doi.org/10.1093/cid/ciz697
• Steinberg, Ruth MD*,†; Marty, Véronique MSc*; Korten, Insa MD, PhD*; Aebi, Christoph MD‡; Latzin, Philipp MD, PhD*; Agyeman, Philipp KA MD‡. Epidemiology and Clinical Characteristics of Human Metapneumovirus Infections in Hospitalized Children in Two Consecutive Postpandemic Years. The Pediatric Infectious Disease Journal 43(4):p e141-e144, April 2024. | DOI: 10.1097/INF.0000000000004221 
• Yi, L., Zou, L., Peng, J. et al. Epidemiology, evolution and transmission of human metapneumovirus in Guangzhou China, 2013–2017. Sci Rep 9, 14022 (2019). https://doi.org/10.1038/s41598-019-50340-8
• https://ictv.global/report/chapter/pneumoviridae/pneumoviridae/metapneumovirus
• https://thenativeantigencompany.com/human-metapneumovirus/
• https://www.cusabio.com/c-21124.html